Dr. Andrew Kung, MD

• Pediatric Hematology & Oncology

• Pediatrics

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Dana Farber Canc Institute Children's Hospital

  Fellowship Hospital, 1999

• Children's Hospital Boston

  Residency Hospital, 1996

• Childrens Hospital Boston

  Internship Hospital, 1995

• Stanford University

  Medical School, 1994

• Stanford University School Of Medicine

  Medical School, 1994

• Desferroxamine infusion increases cerebral blood flow: a potential association with hypoxia-inducible factor-1, 2010-03-29

• Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia, 2009-10-14

• Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors, 2010-08-31

• Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer, 2021-08-17

• A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells, 2013-08-12

• Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation, 2011-07-07

• Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib Potentiation of nilotinib by CXCR4 antagonist, 2011-12-20

• Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma, 2007-04-10

• Smac mimetics: implications for enhancement of targeted therapies in leukemia Treating leukemia with Smac mimetics, 2010-09-16

• BET bromodomain inhibition as a therapeutic strategy to target c-Myc, 2011-09-01

• A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response, 2012-03-18

• Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL, 2015-02-16

• Selective inhibition of BET bromodomains, 2010-09-24

• Co-clinical trials demonstrate superiority of crizotinib to chemotherapy inALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance, 2013-12-10

• Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition, 2013-02-21

• Proteomic and Genetic Approaches Identify Syk as an AML Target, 2009-10-06

• KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-ALL and AML, 2013-02-04

• Inhibition of Inflammatory Arthritis Using Fullerene Nanomaterials, 2015-04-16

• Complementary Genomic Screens Identify SERCA as a Therapeutic Target inNOTCH1Mutated Cancer, 2013-02-21

• Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities, 2013-09-29

• Targeted Disruption of the BCL9/ß-catenin Complex Inhibits Oncogenic Wnt Signaling, 2012-08-22

• An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells, 2010-03-16

• Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target inLKB1Mutant Lung Cancer, 2013-05-28

• HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer, 2017-07-05

• An epigenetic mechanism of resistance to targeted therapy in T-cell acute lymphoblastic leukemia, 2014-03-02

• Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: Synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors, and JAK inhibitors Novel combination therapy approaches to overriding stromal-mediated chemoresistance, 2012-04-03

• Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming, 2011-03-29

• Beneficial effects of combining a Type II ATP competitive inhibitor with an allosteric competitive inhibitor of Bcr-Abl for the treatment of imatinib-sensitive and imatinib resistant CML, 2010-05-27

• A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53, 2010-11-16

• Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia, 2012-05-15